Skip to main content

Table 1 Baseline characteristics of included study participants (n=1782) and their association with all-cause dementia

From: Association of the inflammation-related proteome with dementia development at older age: results from a large, prospective, population-based cohort study

Baseline characteristics

n (%)

All-cause dementia cases

(n=504)

Controls

(n=1278)

χ2 test

p-value

Multivariate odds ratio (95% CI)c

Age (years)

   

< 0.0001

 

 50–64

956 (53.65)

154 (30.56)

802 (62.75)

 

1.00 Ref.

 65–69

458 (25.70)

157 (31.15)

301 (23.55)

 

2.57 (1.96–3.37)

 70–75

368 (20.65)

193 (38.29)

175 (13.69)

 

5.37 (4.03–7.15)

Sex

   

0.2486

 

 Female

965 (54.15)

262 (51.98)

703 (55.01)

 

1.00 Ref.

 Male

817 (45.85)

242 (48.02)

575 (44.99)

 

1.28 (1.01–1.63)

Education (years)

   

0.0868

 

 ≤ 9

1344 (77.42)

391 (80.79)

953 (76.12)

 

1.00 Ref.

 10–11

216 (12.44)

48 (9.92)

168 (13.42)

 

0.84 (0.58–1.23)

 ≥ 12

176 (10.14)

45 (9.30)

131 (10.46)

 

0.93 (0.62–1.38)

Physical activitya

   

< 0.0001

 

 Inactive

383 (21.54)

150 (29.82)

233 (18.27)

 

1.00 Ref.

 Low

814 (45.78)

220 (43.74)

594 (46.59)

 

0.65 (0.49–0.86)

 Medium or high

581 (32.68)

133 (26.44)

448 (35.14)

 

0.60 (0.44–0.83)

BMI (kg/m2)

   

0.5708

 

 < 25

478 (26.91)

144 (28.63)

334 (26.24)

 

1.00 Ref.

 25–<30

832 (46.85)

228 (45.33)

604 (47.45)

 

0.85 (0.65–1.12)

 ≥30

466 (26.24)

131 (26.04)

335 (26.32)

 

0.85 (0.62–1.17)

CVDb

   

< 0.0001

 

 No

1373 (77.05)

350 (69.44)

1023 (80.05)

 

1.00 Ref.

 Yes

409 (22.95)

154 (30.56)

255 (19.95)

 

1.20 (0.92–1.56)

Diabetes

   

0.0001

 

 No

1469 (83.61)

386 (78.14)

1083 (85.75)

 

1.00 Ref.

 Yes

288 (16.39)

108 (21.86)

180 (14.25)

 

1.29 (0.96–1.74)

Life-time history of depression

   

0.0225

 

 No

1527 (85.69)

427 (84.72)

1100 (86.07)

 

1.00 Ref.

 Yes, without current pharmacotherapy

184 (10.33)

47 (9.33)

137 (10.72)

 

1.01 (0.69–1.49)

 Yes, with current pharmacotherapy

71 (3.98)

30 (5.95)

41 (3.21)

 

2.26 (1.33–3.85)

APOE genotypesd

   

< 0.0001

 

 ɛ2/ɛ2

18 (1.09)

1 (0.22)

17 (1.42)

 

0.25 (0.04–1.47)

 ɛ2/ɛ3

238 (14.43)

57 (12.58)

181 (15.13)

 

1.06 (0.75–1.52)

 ɛ2/ɛ4

55 (3.34)

22 (4.86)

33 (2.76)

 

2.77 (1.52–5.06)

 ɛ3/ɛ3

929 (56.34)

218 (48.12)

711 (59.45)

 

1.00 Ref.

 ɛ3/ɛ4

379 (22.98)

135 (29.80)

244 (20.40)

 

1.79 (1.35–2.37)

 ɛ4/ɛ4

30 (1.82)

20 (4.42)

10 (0.84)

 

7.15 (3.18–16.08)

  1. Numbers printed in bold are statistically significant (p < 0.05)
  2. Abbreviations: CI, confidence interval; BMI, body mass index; CVD, cardiovascular disease; APOE, apolipoprotein E
  3. a“Inactive” was defined by < 1 h of vigorous or < 1 h light physical activity per week. “Medium or high” was defined by ≥ 2 h of vigorous and ≥ 2 h of light physical activity/week. All other amounts of physical activity were grouped into the category “Low”
  4. bCVD was defined as coronary artery disease or a self-reported history of myocardial infarction, stroke, pulmonary embolism, or revascularization of coronary arteries
  5. cResults of multivariate logistic regression model for all-cause dementia including all variables shown in this table (imputed dataset)
  6. dAPOE genotypes could not be ascertained for 7.5% of the participants due to problems with DNA extraction in the process of analyses
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193